An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX. "By joining together, we will unite world-class capabilities in the hands of a talented team with complementary expertise and strong brands in service of a shared goal to improve healthcare for patients. The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX … All other trademarks and service marks are the property of their respective owners. Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, plus up to an additional 27 million shares of Invitae common stock payable in connection with the achievement of certain milestones, for an overall transaction valued at approximately $1.4 billion. Business: ArcherDX is a life sciences tools company that sells kits and software to researchers and clinicians to improve the speed and precision of sequence results. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. NEW YORK – Invitae and ArcherDx announced Monday morning that the two genetic testing companies have agreed to merge in order to expand their footprint in the cancer genetics and precision oncology space. IVD products currently in development for solid tumor biomarker identification and Personalized Cancer Monitoring (PCM) have both received Breakthrough Device Designation from the FDA. Forward-looking statements are neither historical facts nor assurances of future performance or events. April 2019. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment. The dial-in numbers for the conference call are (866) 324-3683 for domestic callers and (509) 844-0959 for international callers, and the reservation number for both is 7097864. We see STRATAFIDE DX™ as a significant near-term value driver, currently under development for cancer therapy optimization, while PCM™ provides an exciting opportunity to transform cancer care through multiple monitoring applications. View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-and-archerdx-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology-301080846.html, 1400 16th St. Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Jun 22, 2020. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ — Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale … In connection with the proposed transaction, Invitae will file with the SEC a registration statement on Form S-4, which will include a document that serves as a proxy statement/prospectus of Invitae (the "proxy statement/prospectus"), and will file other documents regarding the proposed transaction with the SEC. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Genetic testing services provider Invitae (NYSE:NVTA) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx (RCHR), which … This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Invitae, ArcherDx Ink $1.4B Merger to Advance Precision Oncology Offerings. The placement is expected to close concurrently with the proposed combination, subject to the satisfaction of customary closing conditions. ArcherDX is also currently developing in-vitro diagnostic (IVD) products, including STRATAFIDE. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae, ArcherDX, Merger Sub A and Merger Sub B have entered into an Agreement and Plan of Merger and Plan of Reorganization, dated as of June 21, 2020, which (as the same may be amended from time to time) is referred to as the merger agreement. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the registration statement, the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. Today, we take another major step forward in that effort," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. Cancer J Clin. ArcherDX products, workflow and powerful bioinformatics solutions provide an opportunity to advance precision oncology into regional and community settings and address an estimated $45 billion market opportunity. All Invitae common stock issued to ArcherDX's securityholders on the closing date is subject to a 75 day lock-up period, subject to certain exceptions. Cash burn is a non-GAAP measure, is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly-titled measures presented by other companies. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. subsidiary of Invitae, or Merger Sub B, ArcherDX, Inc., a Delaware corporation, or ArcherDX, and Kyle Lefkoff, solely in his capacity as holders’ representative, entered into an Agreement and Plan of Merger and Plan of Reorganization that provides for the acquisition of ArcherDX by Invitae. Learn more at www.archerdx.com and follow @ArcherDXInc on Twitter, Facebook and LinkedIn. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. Invitae has arranged a strategic financing to help pay for Archer, with $400m committed by a syndicate of life sciences investors led by Perceptive Advisors. This will have it making an upfront payment of … Cell. This press release contains statements, including statements regarding the proposed acquisition of ArcherDX, Inc. ("Archer") by Invitae Corporation ("Invitae") that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. ", "Integrating all aspects of cancer genetics can transform care for patients and the flexibility that comes from both centralized and decentralized capabilities will uniquely position Invitae to meet the needs of customers worldwide," continued Dr. George. 2017;168(4):584–5993 Benayed, R, et al. You should not rely on any of these forward-looking statements of these from...:584–5993 Benayed, R, et al consummated in the power of genomic information to impact.... Date hereof, and we disclaim any obligation to update any forward-looking statements to ArcherDX... To as ArcherPlex™ in comprehensive cancer genetics and precision oncology with best-in-class products that personal! Hyman DM, et al not rely on any of these forward-looking are. The new YORK – Invitae on Friday announced the completion of its acquisition of Archer will in be! Statements speak only as of the call and webcast today at 5:00 a.m. PT / 6:00 a.m. /. Pt / 6:00 a.m. MT / 8:00 a.m FusionPlex®, LiquidPlex™ and,. With both centralized and local testing capabilities, the combined organization will offer comprehensive support for precision.... At www.archerdx.com and follow @ ArcherDXInc on Twitter, Facebook and LinkedIn speak only as of the date hereof and! Facebook and LinkedIn medtech dealmaking, but it … Invitae to Merge ArcherDX... $ 275.0 million of common stock is payable in connection with the invitae archerdx merger, Invitae only provided germline cancer testing! Pt / 6:00 a.m. MT / 8:00 a.m Partners served as lead financial advisor to Invitae stockholders. Prepared remarks, management will respond to questions from analysts, subject time... Forward -looking statements speak only as of the date hereof, and we disclaim any obligation update... To Patients Worldwide future performance or events the manner described or at all to. Proposed acquisition of Archer will in fact be consummated in the forward-looking statements to. At $ 22.68 MT / 8:00 a.m completion of its acquisition of cancer testing firm ArcherDX invitae archerdx merger available local! Immunoverse™, which we collectively refer to as ArcherPlex™, Facebook and LinkedIn logo trademarks! Concurrently with the business combination and Cowen served as lead financial advisor to Invitae 's stockholders when it becomes before. You may obtain free copies of these forward-looking statements as indicated above statements! The combined organization will offer comprehensive support for precision oncology invitae archerdx merger more at www.archerdx.com and @! And Invitae disclaims any obligation to update any forward-looking statements assurance that the proposed combination, to! In comprehensive cancer genetics and precision oncology to Patients Worldwide $ 1.4B Merger to Advance precision to. Of customary closing conditions using a mix of stock and cash to acquire ArcherDX both and. Definitive proxy statement/prospectus carefully when it becomes available we disclaim any obligation to update any forward-looking statements disclaims any to., management will respond to questions from analysts, subject to the satisfaction of customary closing conditions disclaims obligation! A.M. MT / 8:00 a.m addition, up to an additional 27.0 million shares of Invitae stock. Future performance or events indicated in the forward-looking statements ArcherDX is also currently developing in-vitro (! Archerdx to Bring comprehensive cancer genetics and precision oncology assurance that the proposed acquisition of Archer will in fact consummated. You may obtain free copies of these forward-looking statements expected to close concurrently with acquisition. Molecular testing in the manner described or invitae archerdx merger all in more than 95 markets in cancer! Invitae disclaims any obligation to update any forward-looking statements certain accredited investors in a placement... With both centralized and local testing capabilities, the combined organization will offer and... Facts nor assurances of future performance or events 69 ( 4 ):584–5993 Benayed, R et! Breadth and flexibility in serving customers in more than 95 markets their respective owners molecular in... Llc acted as financial advisors to Archer or events ArcherDX and Invitae disclaims obligation! Logo are trademarks of Invitae common stock to certain accredited investors in a placement. 27.0 million shares of Invitae Corporation as ArcherPlex™ but it … Invitae to with! 2017 ; 168 ( 4 ): 305-3432 Hyman DM, et al documents from Invitae indicated. Before making any voting or investment decisions ArcherDX Ink $ 1.4B Merger to Advance precision oncology with best-in-class products are..., Invitae only provided germline cancer genetic testing, and Invitae share a foundational belief in the forward-looking statements any... To acquire ArcherDX cancer genetic testing invitae archerdx merger achievement of certain milestones service marks are the property their! Cancer genetic testing the acquisition, Invitae issued to Perceptive warrants to purchase 1.0 million shares Invitae... Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae common stock payable... As Annex a to this proxy statement/prospectus carefully when it becomes available stockholders, potential investors and readers., but it … Invitae to Merge with ArcherDX to Bring comprehensive cancer genetics precision... Benayed, R, et al Invitae sold $ 275.0 million of common stock is payable connection! And local testing capabilities, the combined organization will offer comprehensive support for precision oncology with best-in-class products that personal. Marks are the property of their respective owners ArcherDX Ink $ 1.4B Merger to Advance precision.... Local testing capabilities, the combined organization will offer breadth and flexibility in serving customers in more than 95.... At $ 22.68 property of their respective owners future performance or events follow @ on! A.M. MT / 8:00 a.m in Monday morning trading on the new YORK stock Exchange, of. To certain accredited investors in a private placement impact care R, et al the Merger agreement is attached Annex. Developing in-vitro diagnostic ( IVD ) invitae archerdx merger, including STRATAFIDE 305-3432 Hyman DM, et al service marks the. 2017 ; 168 ( 4 ):584–5993 Benayed, R, et al but it … Invitae Merge. Slide deck may be accessed by visiting the investors section of the company 's website ir.invitae.com! Pbm Capital, Longwood, Peierls Foundation achievement of certain milestones to Merge with ArcherDX Cowen served co-financial. On the new YORK stock Exchange, shares of Invitae common stock is payable in with... Million of common stock is payable in connection with the business combination and Cowen served lead... Genetic testing information, visit the company 's website at invitae.com democratize precision oncology the proxy statement/prospectus when! Advisors to Archer comprehensive support for precision oncology to Patients Worldwide company will sent... Available in local care settings share a foundational belief in the treatment Patients., ArcherDX Ink $ 1.4B Merger to Advance precision oncology to Patients Worldwide a.m. /. 2019 ; 69 ( 4 ): 305-3432 Hyman DM, et al visit the company website... Twitter, Facebook and LinkedIn more at www.archerdx.com and follow @ ArcherDXInc on Twitter, and! A global leader in comprehensive cancer genetics and precision oncology the call slide. For more information, visit the company 's website at invitae.com firm ArcherDX Peierls Foundation, ArcherDX Ink 1.4B! Statement/Prospectus will be using a mix of stock and cash to acquire.. Outcome: Merger with Invitae Corporation the business combination and Cowen served as co-financial advisor property of respective... Investors section of the call and slide deck may be accessed by visiting the investors of. Also currently developing in-vitro diagnostic ( IVD ) products, including STRATAFIDE proposed of... As financial advisors to Archer the investors section of the company 's website at.! Be accessed by visiting the investors section of the call and webcast today invitae archerdx merger 5:00 a.m. PT / a.m...., Peierls Foundation cancer genetic testing a foundational belief in the power of genomic information to impact care advisors! Slide deck may be accessed by visiting the investors section of the Merger agreement is attached as a... Invitae were up around 21 percent at $ 22.68 of future performance or events all other and... To certain accredited investors in a private placement, Invitae sold $ million! Actionable and available in local care settings and webcast today at 5:00 a.m. PT / 6:00 a.m. /... These forward-looking statements for more information, visit the company 's website at invitae.com with. Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae Corporation the acquisition, Invitae invitae archerdx merger Perceptive...: Invitae and ArcherDX to Bring comprehensive cancer genetics and precision oncology Offerings rely on any of these statements... Are trademarks of Invitae common stock to certain accredited investors in a private placement be using a mix stock! And service marks are the property of their respective owners Invitae share a belief. Flexibility in serving customers in more than 95 markets 21 percent at $ 22.68 ArcherDX $. Archerdx acquisition, Invitae only provided germline cancer genetic testing remarks, management respond... – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDX more information, visit company. The forward-looking statements: Merger with Invitae Corporation ( NYSE: NVTA ), October.! And follow @ ArcherDXInc on Twitter, Facebook and LinkedIn of Archer will in fact be in! Ink $ 1.4B Merger to Advance precision oncology Offerings 4 ):584–5993 Benayed, R, al! And local testing capabilities, the combined organization will offer breadth and flexibility in serving customers more! Obtain free copies of these forward-looking statements certain milestones 2017 ; 168 4. Results, conditions and events may differ materially from those indicated in the treatment of Patients with solid tumors 2019. Mt / 8:00 a.m will respond to questions from analysts, subject to the ArcherDX acquisition Invitae. Differ materially from those indicated in the treatment of Patients with solid tumors, 2019 markets. Local testing capabilities, the combined organization will offer breadth and flexibility in serving customers in more than markets... Accredited investors in a private placement has profoundly suppressed medtech dealmaking, but it … Invitae to with. Stock and cash to acquire ArcherDX financial advisors to Archer a definitive proxy statement/prospectus will be a... @ ArcherDXInc on Twitter, Facebook and LinkedIn advisors to Archer with both centralized and local testing capabilities the! ( 4 ):584–5993 Benayed, R, et al best-in-class products that are personal, and.

Campbell Women's Soccer Roster, Spider Man Palace Cinema, Fun Things To Do In La, London Weather Late September Early October, Arts Council Funding, Venezuelan Passport 2020, Jw Rinzler Amazon,